

Dean et al. (19) used *in situ* radioligand binding and autoradiography to measure [³H]CP-55940, a non-selective cannabinoid agonist, in the dorsolateral prefrontal cortex (Brodmann's area 9), caudate-putamen, and areas of the temporal lobe and found a significant increase in [³H]CP-55940 binding in the dorsolateral prefrontal cortex in subjects with schizophrenia that was independent of recent cannabis ingestion. They also found an increase in the density of CB₁ receptors in the caudate-putamen that was independent of diagnosis in subjects who had recently ingested cannabis. They speculated that changes in CB₁ receptors in the dorsolateral prefrontal cortex may be associated with the pathology of schizophrenia. Zavitsanou et al. (20) used [³H]SR141716A as a radioligand for quantitative autoradiography of CB₁ receptors because SR141716A is a more potent and selective ligand for CB₁ receptors than CP-55940. They examined the anterior cingulate cortex, which plays an important role in normal cognition, particularly in relation to motivation and attention, and found a statistically significant 64% increase in [³H]SR141716A-specific binding in the schizophrenia group as compared to the control group. These two independent postmortem studies showed an increase of CB₁ receptors in subregions of the prefrontal cortex, dorsolateral and anterior cingulate regions in schizophrenia. The major clinical symptoms observed in schizophrenia are classified into three categories: positive, negative, and disorganized symptoms. Negative symptoms consist of blunting of affect, poverty of speech and thought, apathy, anhedonia, reduced social drive, and loss of motivation. Such negative symptoms, including cognitive impairment, may result from dysfunction of the prefrontal cortex. Because cannabinoids disarrange cognition, attention, and motivation, it is possible that the increased numbers of CB₁ receptors in the prefrontal cortex may be involved in the pathology of schizophrenia particularly in relation to negative symptoms.

Endocannabinoids in cerebrospinal fluid (CSF)

Following the discovery of cannabinoid receptors in the brain, endogenous ligands for cannabinoid receptors were found in mammalian tissues. These are arachidonic acid derivatives. To date, two molecules have been identified as endocannabinoids acting on CB₁ receptors: anandamide (*N*-arachidonyl-ethanolamine) (21) and 2-AG (2-arachidonylglycerol) (22). They are able to reproduce the most typical behavioral effects of Δ^9 -THC, such as inhibition of locomotor activity, analgesia on a hot plate, and hypothermia, in rodents. Therefore, they act as agonists *in vivo* for the cannabinoid systems.

Leweke et al. (23) examined CSF concentrations of endocannabinoids in schizophrenia. They found that CSF levels of anandamide and palmitylethanolamide, another endocannabinoid acting mainly on CB₂ receptors, were increased by twofold in schizophrenic patients compared to non-schizophrenic controls, and 2-AG in the CSF was below detection in both groups. The increase of the two endocannabinoids in the CSF of schizophrenics was not affected by medication. Because increases in the CSF levels of anandamide and palmitylethanolamide should reflect increases in the brain, hyperactivity of the endocannabinoid system in the central nervous system may be involved in the pathogenesis of schizophrenia.

Genetic studies

CB₁ receptors are encoded by the CNR1 gene (MIM114610), which was cloned by Matsuda et al. in 1992 (24). CB₁ is located at 6q14–q15, a site including a schizophrenia susceptibility locus, 6q13–q26, which was designated as the Schizophrenia 5 locus (SCZ5, OMIM 603175), as revealed by Cao et al. (25) using two independent series of pedigrees. Two polymorphisms, an AAT-repeat microsatellite in the 3' flanking region and a 1359 G/A polymorphism at codon 453, a silent mutation, in the coding exon of the CNR1 gene, were reported previously. Additional screening of the promoter and entire coding region of the CNR1 gene by direct sequencing revealed two novel polymorphisms, 843G/C and L352S (26); however, their heterozygosities were as low as 1%, and the estimated genetic significance may be small. Therefore, the association with schizophrenia was studied using the AAT repeat and 1359 G/A polymorphisms of the CNR1 gene (27). Although the genotypic and allelic distribution of the 1359 G/A polymorphism was not different in schizophrenic and control subjects in a Japanese population, which is consistent with a Caucasian study (28), allelic distributions of the AAT-repeat polymorphism differed significantly between them (Fig. 2). Schizophrenia is usually divided into three subtypes by clinical features: paranoid, hebephrenic, and catatonic types. The hebephrenic subtype of schizophrenia, but not others, showed a strong association with the CNR1 gene ($P = 0.0028$). The 9-repeat allele of the AAT-repeat polymorphism was a genetic risk factor for susceptibility to hebephrenic schizophrenia (odds ratio = 2.3), and the 17-repeat allele of it was a strong negative risk factor, thus protecting against susceptibility to hebephrenic schizophrenia (odds ratio = 0.21). Namely, an individual with a 9- or 17-repeat allele should have a risk of hebephrenic schizophrenia increased by about twice




Fig. 2. Association of AAT-repeat polymorphism of the CNR1 gene with schizophrenia. * $P < 0.05$. Data from Ref. 27.

and decreased by one fifth, respectively, compared to an individual without either allele. This finding was not supported by a Chinese study (29), in which schizophrenia was examined only in total rather than by subtypes. Although further investigation in different populations is needed to confirm the significance of the CNR1 gene as a genetic risk factor for hebephrenic schizophrenia, the relationship between hebephrenic schizophrenia and the CNR1 gene is very intriguing. Clinical studies have reported that long-term cannabis use causes a combination of symptoms including cognitive impairment, lack of motivation, and impaired attention, the so-called “amotivational syndrome,”

which resembles the core negative symptoms of schizophrenia (30). Hebephrenic schizophrenia is characterized by disorganized symptoms and also progressive deterioration of negative symptoms such as blunted affect and abulia. We have also consistently found that the CNR1 gene is not associated with methamphetamine psychosis, which shows resemblance to the paranoid type but not the hebephrenic type of schizophrenia, because it has few negative symptoms (unpublished data). The genetic evidence indicates that enhanced endocannabinoid activity may be involved in the negative symptoms of schizophrenia.

Fatty acid amide hydrolase (FAAH, MIM 602935) serves as a primary and rapid catabolic regulator of anandamide, 2-AG, and related fatty acid amide-signaling molecules in vivo (31). FAAH knock-out mice exhibit a 15-fold augmentation of endogenous brain levels of anandamide and an array of intense CB₁-receptor-dependent behavioral responses, including hypomotility, analgesia, catalepsy, and hypothermia (32). Recently, the Pro129Thr missense and functional mutation was identified in the FAAH gene. Sipe et al. (33) found that its homozygous form is strongly associated with both street-drug use and problem drug/alcohol use. However, we have found that there is no association between the Pro129Thr mutation of the FAAH gene and susceptibility to schizophrenia in a Japanese population (34). Possible involvement of the gene in negative symptoms of schizophrenia including cognitive function should be elucidated.




Fig. 3. Cannabinoid system and schizophrenia.

Conclusion

Several lines of biological and genetic evidence that support the cannabinoid hypothesis for schizophrenia are summarized in Fig. 3. Enhanced signaling of the cannabinoid system due to heavy consumption of exogenous cannabis, for example, marijuana, or increased endocannabinoid anandamide, which is mediated by CB₁ receptors in the brain, could precipitate schizophrenia. Increased CB₁ receptor density in the prefrontal cortex of schizophrenic patients should facilitate neural transmission of cannabinoids. In addition, genetic variants of the CNR1 gene, which encodes CB₁ receptors, could alter the efficiency of the receptor function or expression rate of the receptor molecules. All of the various findings observed in schizophrenia could converge into hyperactivity of the cannabinoid systems in the brain, which should play an important role in the pathogenesis of schizophrenia. Particularly, it is most significant clinically that the possible involvement of the cannabinoid system in the neural basis for the negative symptoms of schizophrenia. The recent development of atypical neuroleptics, for example, clozapine, olanzapine, and risperidone, is greatly beneficial to schizophrenic patients because they have been reported to improve not only positive but also negative symptoms with fewer adverse effects than conventional neuroleptics. However, the degree of improvement is not sufficient, especially in negative symptoms. More effective therapy for negative symptoms should be sought. The cannabinoid hypothesis of schizophrenia could be a key to development of an innovative therapy and comprehensive understanding of the etiology of schizophrenia.

References

- Halikas JA, Goodwin DW, Guze SB. Marijuana use and psychiatric illness. *Arch Gen Psychiatry*. 1972;27:162-165.
- Spencer DJ. Cannabis-induced psychosis. *Int J Addict*. 1971;6:323-326.
- McGuire PK, Jones P, Harvey I, Bebbington P, Toone B, Lewis S, et al. Cannabis and acute psychosis. *Schizophr Res*. 1994;13:161-167.
- Johns A. Psychiatric effects of cannabis. *Br J Psychiatry*. 2001;178:116-122.
- Chopra GS, Smith JW. Psychotic reactions following cannabis use in East Indians. *Arch Gen Psychiatry*. 1974;30:24-27.
- Emrich HM, Leweke FM, Schneider U. Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. *Pharmacol Biochem Behav*. 1997;56:803-807.
- Negrete JC. Cannabis and schizophrenia. *Br J Addict*. 1989;84:349-351.
- Turner WM, Tsuang MT. Impact of substance abuse on the course and outcome of schizophrenia. *Schizophr Bull*. 1990;16:87-95.
- Treffert DA. Marijuana use in schizophrenia: a clear hazard. *Am J Psychiatry*. 1978;135:1213-1215.
- Breakey WR, Goodell H, Lorenz PC, McHugh PR. Hallucinogenic drugs as precipitants of schizophrenia. *Psychol Med*. 1974;4:255-261.
- Martinez-Arevalo MJ, Calcedo-Ordonez A, Varo-Prieto JR. Cannabis consumption as a prognostic factor in schizophrenia. *Br J Psychiatry*. 1994;164:679-681.
- Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. *Arch Gen Psychiatry*. 1994;51:273-279.
- Cohen M, Klein DF. Drug abuse in a young psychiatric population. *Am J Orthopsychiatry*. 1970;40:448-455.
- Barbee JG, Clark PD, Crapanzano MS, Heintz GC, Kehoe CE. Alcohol and substance abuse among schizophrenic patients presenting to an emergency psychiatric service. *J Nerv Ment Dis*. 1989;177:400-407.
- McGuire PK, Jones P, Harvey I, Williams M, McGuffin P, Murray RM. Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. *Schizophr Res*. 1995;15:277-281.
- Miller P, Lawrie SM, Hodges A, Clafferty R, Cosway R, Johnstone EC. Genetic liability, illicit drug use, life stress and psychotic symptoms: preliminary findings from the Edinburgh study of people at high risk for schizophrenia. *Soc Psychiatry Psychiatr Epidemiol*. 2001;36:338-342.
- Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. *Lancet*. 1987;2:1483-1486.
- Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. *Mol Pharmacol*. 1988;34:605-613.
- Dean B, Sundram S, Bradbury R, Scarr E, Copolov D. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. *Neuroscience*. 2001;103:9-15.
- Zavitsanou K, Garrick T, Huang XF. Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry*. 2004;28:355-360.
- Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science*. 1992;258:1946-1949.
- Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. *Biochem Pharmacol*. 1995;50:83-90.
- Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. Elevated endogenous cannabinoids in schizophrenia. *Neuroreport*. 1999;10:1665-1669.
- Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. *Nature*. 1990;346:561-564.
- Cao Q, Martinez M, Zhang J, Sanders AR, Badner JA, Cravchik A, et al. Suggestive evidence for a schizophrenia susceptibility locus on chromosome 6q and a confirmation in an independent

- series of pedigrees. *Genomics*. 1997;43:1-8.
- 26 Iwara N, Suzuki T, Kitajima T, Yamanouchi Y, Ikeda M, Inada T, et al. Mutation screening of the human cannabinoid receptor 1 (CNR1) in Japanese schizophrenia. *Am J Med Genet*. 2003;122B:113
- 27 Ujike H, Takaki M, Nakata K, Tanaka Y, Takeda T, Kodama M, et al. CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. *Mol Psychiatry*. 2002;7:515-518.
- 28 Leroy S, Griffon N, Bourdel MC, Olie JP, Poirier MF, Krebs MO. Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1. *Am J Med Genet*. 2001;105:749-752.
- 29 Tsai SJ, Wang YC, Hong CJ. Association study of a cannabinoid receptor gene (CNR1) polymorphism and schizophrenia. *Psychiatr Genet*. 2000;10:149-151.
- 30 Kupfer DJ, Detre T, Koral J, Fajans P. A comment on the "amotivational syndrome" in marijuana smokers. *Am J Psychiatry*. 1973;130:1319-1322.
- 31 Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. *Nature*. 1996;384:83-87.
- 32 Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. *Proc Natl Acad Sci USA*. 2001;98:9371-9376.
- 33 Sipe JC, Chiang K, Gerber AL, Beutler E, Cravatt BF. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. *Proc Natl Acad Sci USA*. 2002;99:8394-8399.
- 34 Morita Y, Ujike H, Tanaka Y, Uchida N, Nomura A, Ohtani K, et al. A nonsynonymous polymorphism in the human fatty acid amide hydrolase gene did not associate with either methamphetamine dependence or schizophrenia. *Neurosci Lett*. In press.



A nonsynonymous polymorphism in the human fatty acid amide hydrolase gene did not associate with either methamphetamine dependence or schizophrenia

Yukitaka Morita^a, Hiroshi Ujike^{a,b,*}, Yuji Tanaka^{a,b}, Naohiko Uchida^a, Akira Nomura^a, Kyohei Ohtani^a, Makiko Kishimoto^a, Akiko Morio^a, Takaki Imamura^a, Ayumu Sakai^a, Toshiya Inada^{b,c}, Mutsuo Harano^{b,d}, Tokutaro Komiyama^{b,e}, Mitsuhiko Yamada^{b,f}, Yoshimoto Sekine^{b,g}, Nakao Iwata^{b,h}, Masaomi Iyo^{b,i}, Ichiro Sora^{b,j}, Norio Ozaki^{b,i}, Shigetoshi Kuroda^a

^a Department of Neuropsychiatry, Okayama University Graduate School of Medicine and Dentistry, 2-5-1 Shikata-cho, Okayama 700-8558, Japan

^b Japanese Genetics Institute for Drug Abuse, Japan

^c Department of Psychiatry and Psychobiology, Nagoya University Graduate School of Medicine, Nagoya, Japan

^d Department of Neuropsychiatry, Kurume University Graduate School of Medicine, Kurume, Japan

^e Division of Psychiatry, National Center Hospital for Mental, Nervous and Muscular Disorders, National Center of Neurology and Psychiatry, Tokyo, Japan

^f National Institute of Mental Health, National Center of Neurology and Psychiatry, Ichikawa, Japan

^g Department of Psychiatry and Neurology, Hamamatsu University School of Medicine, Hamamatsu, Japan

^h Department of Psychiatry, Fujita Health University School of Medicine, Houmei, Japan

ⁱ Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan

^j Division of Psychobiology, Department of Neuroscience, Tohoku University Graduate School of Medicine, Sendai, Japan

Received 8 October 2004; received in revised form 11 November 2004; accepted 17 November 2004

Abstract

Genetic contributions to the etiology of substance abuse and dependence are topics of major interest. Acute and chronic cannabis use can produce drug-induced psychosis resembling schizophrenia and worsen positive symptoms of schizophrenia. The endocannabinoid system is one of the most important neural signaling pathways implicated in substance abuse and dependence. The fatty acid amide hydrolase (FAAH) is a primary catabolic enzyme of endocannabinoids. To clarify a possible involvement of FAAH in the etiology of methamphetamine dependence/psychosis or schizophrenia, we examined the genetic association of a nonsynonymous polymorphism of the FAAH gene (Pro129Thr) by a case-control study. We found no significant association in allele and genotype frequencies of the polymorphism with either disorder. Because the Pro129Thr polymorphism reduces enzyme instability, it is unlikely that dysfunction of FAAH and enhanced endocannabinoid system induce susceptibility to either methamphetamine dependence/psychosis or schizophrenia.

© 2004 Elsevier Ireland Ltd. All rights reserved.

Keywords: The fatty acid amide hydrolase (FAAH); Methamphetamine dependence/psychosis; Schizophrenia; Nonsynonymous polymorphism; The Pro129Thr polymorphism

In 1988, the existence of a cannabinoid receptor in the brain was found, and its gene was cloned two years later [7,19]. To

date, at least two different cannabinoid receptors, CB1, CB2, and putative endogenous agonists, including anandamide and 2-arachidonylglycerol, have been identified [8]. CB1 receptors are the only cannabinoid receptors that have been found in the central nervous system (CNS). A number of studies

* Corresponding author. Tel.: +81 86 235 7242; fax: +81 86 235 7246.
E-mail address: hujike@cc.okayama-u.ac.jp (H. Ujike).

have indicated that brain CB1 receptors mediate the behavioral and neurochemical properties of cannabis, e.g., marijuana, including the rewarding effect, tolerance, and physical dependence [9,24,30]. CB1 receptors and endogenous agonists are involved not only in cannabinoid dependence but also dependence on other classes of drugs, such as alcohol, morphine, and cocaine [11,22,23,38]. Interaction between cannabinoids and amphetamines, including methamphetamine, has also been reported. Thus, the cannabinoid receptor antagonist AM251 inhibited methamphetamine self-administration by reduction of methamphetamine withdrawal [37]. Another antagonist, SR141716A, potentiated the stimulating effects of amphetamine [18]. The CB1 agonist WIN 55, 212-2 or delta 9-tetrahydrocannabinol, a main ingredient of cannabis, induced cross-sensitization to amphetamine [14,21]. These findings implicate the endocannabinoid system as one of the most important signaling pathways in drug abuse and dependence.

In the 1980s, fatty acid amide hydrolase (FAAH), the integral membrane cannabinoid enzyme, was identified [27]. FAAH is widely expressed in neuronal cells in the CNS, predominantly in the neocortex, hippocampal formation, amygdala, and cerebellum [10,31]. FAAH serves as a primary catabolic regulator of the endogenous cannabinoid ligand anandamide and related fatty acid amide-signaling molecules [15,16]. It has been reported that the metabolic activity of FAAH plays important roles in the CNS by ensuring rapid termination of specific signaling processes of the cannabinoid system [3–5]. Mice lacking FAAH (FAAH $-/-$ mice) are severely impaired in their ability to degrade anandamide. As a consequence, the brain level of anandamide in FAAH $-/-$ mice is increased 15-fold, and they exhibit CB1 receptor-dependent behavioral responses, including less sensitivity to several pain stimuli, hypomotility, hypothermia, analgesia, and catalepsy [2]. Mutation of the FAAH gene may induce dysregulation of the endogenous cannabinoid system, and result in alternation in brain addiction/reward pathways. Recently, Sipe et al. [28] reported that the presence of a polymorphism of the FAAH gene that converts a conserved proline residue to threonine at the 129 position (Pro129Thr) is a risk factor for problem substance abuse and dependence in a Caucasian population. We tried to determine if a genetic association of the Pro129Thr nonsynonymous polymorphism of the FAAH gene in patients with methamphetamine dependence in a Japanese population.

Furthermore, acute and chronic cannabis exposure can precipitate a psychotic state, with hallucinations and delusions resembling schizophrenia. Cannabis consumption also worsens positive symptoms of schizophrenia, and could result in a poor outcome and liability to relapse [12,13,20,29,32]. Two cohort studies showed cannabis use in adolescence increased greatly the risk of schizophrenia in adulthood [1,39]. In addition, recent studies showed an increased density of CB1 receptors in the prefrontal cortex and an increased level of anandamide in the CSF in schizophrenia [6,17,40]. These findings led to a cannabinoid hypothesis of

schizophrenia [34]. Therefore, we examined a possible association between Pro129Thr polymorphism of the FAAH gene and schizophrenia.

The subjects were 153 patients with methamphetamine dependence (124 males and 29 females; mean age, 37.8 years; S.D. 12.1 years) meeting the ICD-10-DCR criteria (F15.2), who were outpatients or inpatients in psychiatric hospitals of the Japanese Genetics Initiative for Drug Abuse (JGIDA), and 200 age-, gender-, and geographical origin-matched normal controls (designated Control-1, 162 males and 38 females; mean age, 37.3 years; S.D. 12.1 years), who were mostly medical staff members without a past individual or family history of drug dependence or psychotic disorders. One hundred and forty-one of patients also suffered from methamphetamine psychosis (F15.5, 118 males and 23 females; mean age, 38.5 years; S.D. 12.1 years). The patients with methamphetamine dependence and/or psychosis were divided into several subgroups by clinical features according to age at first consumption, latency of psychosis, prognosis, and multi-substance abuse status. Seventy-six patients (49.7%) had consumed methamphetamine before the age 20 years, and 77 patients (50.3%) had first consumed methamphetamine after they were 20 years old. The latency of psychosis was less than 3 years after the first methamphetamine consumption in 60 patients (42.6%) and 3 or more years in 81 patients (57.4%). Forty-eight patients (31.4%) had abused only methamphetamine during their lifetime, and 105 patients (68.6%) had abused drugs other than methamphetamine in the past or present. Besides methamphetamine, organic solvents were the most frequently abused drugs, followed by marijuana. Cocaine and heroin were rarely abused. The prognosis of methamphetamine psychosis varied among patients, and some patients showed continuous psychotic symptoms even after methamphetamine discontinuance, as previously reported [25,26]. Therefore, patients were divided into two categories of psychosis, the transient type and the prolonged type, based on the duration of the psychotic state after methamphetamine discontinuance, as described in our previous study [36]. Patients with the transient type showed remission of psychotic symptoms within one month after the discontinuance of methamphetamine consumption and beginning of treatment with neuroleptics, and those with the prolonged type had psychosis that continued for more than one month even after this discontinuance of methamphetamine consumption and beginning of neuroleptic treatment. In this study, 85 patients (60.3%) were the transient type and 56 patients (39.7%) were the prolonged type. It has been well-documented that once methamphetamine psychosis has developed, patients in the remission state become liable to spontaneous relapse without reconsumption of methamphetamine [25,26,35]. Such enhanced liability to relapse may result from a sensitization phenomenon developed during methamphetamine abuse, and may be affected by genetic traits [33]. Therefore, the patients were divided into two groups according to the presence or absence of spontaneous relapse. The number of patients with a history of

spontaneous relapse was 65 (46.1%) and those without were 76 (53.9%).

To determine the relationship between the Pro129Th polymorphism and schizophrenia, we examined 260 patients (151 males and 109 females; mean age, 44.5 years; S.D. 13.1 years) fulfilling the ICD-10 diagnostic criteria for schizophrenia. Assessment for diagnosis and subtype of schizophrenia was performed by trained psychiatrists on the basis of all available information, including hospital notes. One hundred and twenty-seven patients (68 males and 59 females; mean age, 39.1 years; S.D. 13.1 years) were diagnosed with the paranoid type, 127 (82 males and 45 females; mean age, 39.6 years; S.D. 13.9 years) with the hebephrenic type, 2 with the catatonic type, and 4 residual type of schizophrenia. Age-, gender-, and geographical origin-matched control subjects for the schizophrenia patients were recruited (designated Control-2, 194 males and 143 females; mean age, 47.2 years; S.D. 11.8 years). Subjects with a positive personal or familial history of major psychiatric disorders were excluded from the control group. This study was performed after obtaining approval from the ethics committees of each institute of JGIDA, and all subjects provided written informed consent for the use of their DNA samples in this research.

The genomic DNA was extracted from peripheral leukocytes using the standard phenol/CHCl₃ method. A Pro129Th polymorphism of the FAAH gene was amplified by polymerase chain reaction (PCR), with 3% dimethyl sulfoxide and 0.75 units of Taq DNA polymerase in a total volume of 15 μ l reaction mixture using the following primer sets: 5'-ATG TTG CTG GTT ACC CCT CTC C-3' and 5'-TCA CAG GGA CGC CAT AGA GCT G-3'. Initial denaturation was performed for 5 min at 95 °C. Then, 35 cycles were performed (30 s of denaturing at 95 °C, 30 s of annealing at the appropriate temperature, and 30 s of extension at 72 °C), followed by a final extension at 72 °C for 5 min. The PCR products were then digested with EcoO109I and analyzed on 3.0% agarose gels.

Deviation of the genotype counts from Hardy–Weinberg equilibrium was tested using a chi-square goodness-of-fit test. The statistical significance of differences in the genotype distribution and allele frequency between patients and controls was assessed by a chi-square test or Fisher's exact test at a significance level of 0.05. All genotyping was performed in a blinded fashion, with the control and case samples mixed randomly. Allele frequencies were calculated using allele-counting methods.

The genotype distribution and allele frequencies of Pro129Th polymorphism of the FAAH gene for patients with methamphetamine dependence/psychosis or schizophrenia, Control-1, and Control-2 are shown in Tables 1 and 2. The genotype distribution of all patients and controls subjects did not deviate significantly from Hardy–Weinberg equilibrium at the polymorphic locus. No significant differences were found in the frequency of the genotype or allele of the Pro129Th polymorphism between patients with methamphetamine dependence and Control-1 (geno-

type, $\chi^2 = 1.22$, d.f. = 2, $P = 0.57$; allele, $\chi^2 = 0.22$, d.f. = 1, $P = 0.68$). No significant differences were found in the frequency of the genotype or allele between subcategories of methamphetamine-dependent patients whose age at first methamphetamine consumption was less than 20 years or more than 20 years (genotype, $\chi^2 = 1.80$, d.f. = 2, $P = 0.45$; allele, $\chi^2 = 0.65$, d.f. = 1, $P = 0.45$). Nor was there a significant difference between patients with and without multiple substance abuse (genotype, $\chi^2 = 2.01$, d.f. = 2, $P = 0.49$; allele, $\chi^2 = 0.60$, d.f. = 1, $P = 0.52$), or patients whose latency of methamphetamine-induced psychosis was less than 3 years (genotype, $\chi^2 = 0.66$, d.f. = 2, $P = 0.75$; allele, $\chi^2 = 0.51$, d.f. = 1, $P = 0.52$), or between patients with transient and prolonged psychosis (genotype, $\chi^2 = 3.26$, d.f. = 2, $P = 0.19$; allele, $\chi^2 = 3.08$, d.f. = 1, $P = 0.11$), or patients with and without spontaneous relapse of psychotic symptoms (genotype, $\chi^2 = 4.56$, d.f. = 2, $P = 0.16$; allele, $\chi^2 = 4.36$, d.f. = 1, $P = 0.06$).

No significant differences were found in the frequency of the genotype or allele of the Pro129Th polymorphism between schizophrenia patients and Control-2 (genotype, $\chi^2 = 0.18$, d.f. = 2, $P = 0.91$; allele, $\chi^2 = 0.01$, d.f. = 1, $P = 0.94$). With regard to the subcategories of schizophrenia, no significant differences were found in the frequency of the genotype or allele between patients with paranoid type schizophrenia and Control-2 (genotype, $\chi^2 = 0.67$, d.f. = 2, $P = 0.63$; allele, $\chi^2 = 0.02$, d.f. = 1, $P = 0.92$), or patients with hebephrenic type schizophrenia and Control-2 (genotype, $\chi^2 = 1.15$, d.f. = 2, $P = 0.61$; allele, $\chi^2 = 0.32$, d.f. = 1, $P = 0.62$).

FAAH is a primary and rapid catabolizer of endocannabinoids, such as anandamide and 2-arachidonoyl glycerol, and FAAH knockout mice show a robust increase in brain anandamide. Therefore, homozygosity of a mutant allele of the gene may induce hyperactivity of cannabinoid signaling in the brain. The present study showed no significant association between methamphetamine dependence/psychosis and the Pro129Th nonsynonymous polymorphism of the FAAH gene. Sipe et al. [28] reported that the Pro129Th polymorphism is strongly associated with street-drug use and problem drug/alcohol use, especially with illegal drug use by Caucasians. They found that the odds ratios of the mutant 129Th/Thr homozygote for risk of problem drug/alcohol use and street-drug use in individuals were 4.5 and 2.2, respectively [28]. The Pro129Th mutation did not significantly impact the catalytic properties of FAAH, but it was found to produce a significantly greater sensitivity to proteolytic degradation, and may have direct effects on the regulation of the FAAH proteins [28]. These findings suggest that dysfunction of FAAH and enhanced endocannabinoid level due to genetic mutation may constitute a risk factor for problem drug use. However, our data indicated that dysfunction of FAAH did not affect the risk of methamphetamine dependence/psychosis in a Japanese population. We also examined a possible association between clinical features of methamphetamine dependence/psychosis, such as age at first methamphetamine

Table 1
Fatty acid amide hydrolase (FAAH) genotype distributions and allele frequency in patients with methamphetamine (METH) dependence/psychosis

Group	N	Genotype			P-value	Allele		P-value
		Pro/Pro (%)	Pro/Thr (%)	Thr/Thr (%)		Pro (%)	Thr (%)	
Control-1	200	139 (69.5)	58 (29.0)	3 (1.5)		336 (84.0)	64 (16.0)	
METH dependence/psychosis	153	105 (68.6)	43 (28.1)	5 (3.3)	0.57	253 (82.7)	53 (17.3)	0.68
Age of first use								
<20 years	76	49 (64.5)	25 (32.9)	2 (2.6)		123 (81.0)	29 (19.1)	
≥20 years	77	56 (72.7)	18 (23.4)	3 (3.9)	0.45	130 (84.4)	24 (15.6)	0.45
Multi-substance abuse								
No	48	30 (62.5)	17 (35.5)	1 (2.1)		77 (80.2)	19 (19.8)	
Yes	105	75 (71.4)	26 (24.8)	4 (3.8)	0.49	176 (83.8)	34 (16.2)	0.52
Latency of psychosis								
<3 years	60	43 (71.7)	16 (26.7)	1 (1.7)		102 (85.0)	18 (15.0)	
≥3 years	81	54 (66.7)	24 (29.6)	3 (3.7)	0.75	132 (81.5)	30 (18.5)	0.52
Prognosis of psychosis								
Transient	85	53 (62.4)	29 (34.1)	3 (3.5)		135 (79.4)	35 (20.6)	
Prolonged	56	43 (76.8)	12 (21.4)	1 (1.8)	0.19	98 (87.5)	14 (12.5)	0.11
Spontaneous relapse of psychotic symptoms								
No	76	47 (61.8)	26 (34.2)	3 (3.9)		120 (78.9)	32 (21.1)	
Yes	65	50 (76.9)	14 (21.5)	1 (1.5)	0.16	114 (87.7)	16 (12.3)	0.06

Numbers in parentheses indicate percentages. Statistical analysis was performed by a chi-square test or Fisher's exact test.

Table 2
FAAH genotype distributions and allele frequency in schizophrenia patients

Group	N	Genotype			P-value	Allele		P-value
		Pro/Pro (%)	Pro/Thr (%)	Thr/Thr (%)		Pro (%)	Thr (%)	
Control-2	337	233 (69.1)	99 (29.4)	5 (1.5)		565 (84.0)	109 (16.0)	
Schizophrenia	260	180 (69.2)	75 (28.8)	5 (1.9)	0.91	435 (83.7)	85 (16.3)	0.94
Paranoid type	127	90 (70.9)	34 (26.8)	3 (2.4)	0.63	214 (84.3)	40 (15.7)	0.92
Hebephrenic type	127	83 (65.4)	43 (33.9)	1 (0.0)	0.61	209 (82.3)	45 (17.7)	0.62

Numbers in parentheses indicate percentages. Statistical analysis was performed by a chi-square test or Fisher's exact test.

consumption, latency to onset of psychosis, prognosis, spontaneous relapse, and multi-substance abuse status but found no significant association with any clinical feature. The discrepancy between the previous and present findings may result from differences of substance class. The present study analyzed methamphetamine abusers, however, Spine et al. analyzed "street-drug users". Although, they did not specify the kinds of drugs in their paper, marijuana use has been epidemic in the US, followed by cocaine and morphine. It is possible that the majority of patients examined in the previous study abuse marijuana and that is why the "street-drug use" of the previous study was associated with a mutant allele of the FAAH gene. This hypothesis should be addressed in future study. Alternatively, the ethnicity of the subjects must be considered. Our subjects were Japanese, and theirs were Caucasian. Japanese controls showed the 129Thr allele at 14.6–16.0%, compared to Caucasians at 28.3–30.6%. Homozygosity of the mutant allele was observed in only 1.5% of Japanese subjects. The rarity of the mutant homozygote in our Japanese population may result in a lack of genetic risk of the FAAH gene for Japanese "street-drug users".

No significant association with the Pro129Thr nonsynonymous polymorphism of the FAAH gene with schizophrenia was revealed. This is consistent with Sipe's study of a Caucasian population. Previously, we reported that a triplet repeat polymorphism of the CNR1 gene, which encodes the human CB1 cannabinoid receptor, was significantly associated with patients with schizophrenia, especially the hebephrenic subtype [36]. Several clinical studies have shown that exogenous cannabinoid ligands could precipitate schizophrenia, worsen prognosis, and induce relapse. Our present and previous genetic findings of the endocannabinoid system indicated that variants of cannabinoid receptors, rather than an altered endogenous agonist produced by the FAAH variant, may be important in the etiology of schizophrenia.

The power analysis showed that the present sample size had a power of 0.89 and 0.98 to detect a small effect size ($w = 0.12$) at an alpha value of 0.05 to detect significant allelic associations between Control-1 and total methamphetamine patients and between Control-2 and total schizophrenic patients, respectively. The present total sample size can be therefore considered to be large enough statistically. However, the

statistical power deteriorated in the analysis with regard to the subgroups of patients, and our results must be verified with a larger sample to conclude.

In conclusion, the cannabinoid pathway may be implicated in drug abuse, addiction, and also the pathophysiology of schizophrenia, but the Pro129Thr nonsynonymous polymorphism of the FAAH gene is not significantly associated with either methamphetamine dependence/psychosis or schizophrenia, at least in a Japanese population.

Acknowledgements

The authors are grateful to the Zikei Institute of Psychiatry (Okayama, Japan), the Ministry of Health, Labour and Welfare of Japan, and the Ministry of Education, Culture, Sports, Science and Technology of Japan for support in part by grants.

References

- [1] L. Arseneault, M. Cannon, R. Poulton, R. Murray, A. Caspi, T.E. Moffitt, Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study, *Br. Med. J.* 325 (2002) 1212–1213.
- [2] B.F. Cravatt, K. Demarest, M.P. Patricelli, M.H. Bracey, D.K. Giang, B.R. Martin, A.H. Lichtman, Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase, *Proc. Natl. Acad. Sci. U.S.A.* 98 (2001) 9371–9376.
- [3] B.F. Cravatt, D.K. Giang, S.P. Mayfield, D.L. Boger, R.A. Lerner, N.B. Gilula, Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides, *Nature* 384 (1996) 83–87.
- [4] B.F. Cravatt, A.H. Lichtman, Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system, *Curr. Opin. Chem. Biol.* 7 (2003) 469–7475.
- [5] B.F. Cravatt, O. Prospero-Garcia, G. Siuzdak, N.B. Gilula, S.J. Henriksen, D.L. Boger, R.A. Lerner, Chemical characterization of a family of brain lipids that induce sleep, *Science* 268 (1995) 1506–1509.
- [6] B. Dean, S. Sundram, R. Bradbury, E. Scarr, D. Copolov, Studies on [³H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use, *Neuroscience* 103 (2001) 9–15.
- [7] W.A. Devane, F.A. Dysarz 3rd, M.R. Johnson, L.S. Melvin, A.C. Howlett, Determination and characterization of a cannabinoid receptor in rat brain, *Mol. Pharmacol.* 34 (1988) 605–613.
- [8] W.A. Devane, L. Hanus, A. Breuer, R.G. Pertwee, L.A. Stevenson, G. Griffin, D. Gibson, A. Mandelbaum, A. Etinger, R. Mechoulam, Isolation and structure of a brain constituent that binds to the cannabinoid receptor, *Science* 258 (1992) 1946–1949.
- [9] V. Di Marzo, F. Berrendero, T. Bisogno, S. Gonzalez, P. Cavaliere, J. Romero, M. Cebeira, J.A. Ramos, J.J. Fernandez-Ruiz, Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9-tetrahydrocannabinol-tolerant rats, *J. Neurochem.* 74 (2000) 1627–1635.
- [10] D.K. Giang, B.F. Cravatt, Molecular characterization of human and mouse fatty acid amide hydrolases, *Proc. Natl. Acad. Sci. U.S.A.* 94 (1997) 2238–2242.
- [11] S. Gonzalez, M.G. Cascio, J. Fernandez-Ruiz, F. Fezza, V. Di Marzo, J.A. Ramos, Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine, *Brain Res.* 954 (2002) 73–81.
- [12] J.A. Halikas, D.W. Goodwin, S.B. Guze, Marijuana use and psychiatric illness, *Arch. Gen. Psychiatry* 27 (1972) 162–165.
- [13] A. Johns, Psychiatric effects of cannabis, *Br. J. Psychiatry* 178 (2001) 116–122.
- [14] S. Lamarque, K. Taghzouti, H. Simon, Chronic treatment with delta(9)-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroin. Implications for vulnerability to drug addiction, *Neuropharmacology* 41 (2001) 118–129.
- [15] R.A. Lerner, G. Siuzdak, O. Prospero-Garcia, S.J. Henriksen, D.L. Boger, B.F. Cravatt, Cerebrodiene: a brain lipid isolated from sleep-deprived cats, *Proc. Natl. Acad. Sci. U.S.A.* 91 (1994) 9505–9508.
- [16] J.T. Leuschner, D.R. Wing, D.J. Harvey, G.A. Brent, C.E. Dempsey, A. Watts, W.D. Paton, The partitioning of delta 1-tetrahydrocannabinol into erythrocyte membranes in vivo and its effect on membrane fluidity, *Experientia* 40 (1984) 866–868.
- [17] F.M. Leweke, A. Giuffrida, U. Wurster, H.M. Emrich, D. Piomelli, Elevated endogenous cannabinoids in schizophrenia, *NeuroReport* 10 (1999) 1665–1669.
- [18] J.M. Masserano, F. Karoum, R.J. Wyatt, SR 141716A, a CB1 cannabinoid receptor antagonist, potentiates the locomotor stimulant effects of amphetamine and apomorphine, *Behav. Pharmacol.* 10 (1999) 429–432.
- [19] L.A. Matsuda, S.J. Lolait, M.J. Brownstein, A.C. Young, T.I. Bonner, Structure of a cannabinoid receptor and functional expression of the cloned cDNA, *Nature* 346 (1990) 561–564.
- [20] P.K. McGuire, P. Jones, I. Harvey, P. Bebbington, B. Toone, S. Lewis, R.M. Murray, Cannabis and acute psychosis, *Schizophr. Res.* 13 (1994) 161–167.
- [21] J.W. Muschamp, S.M. Siviyy, Behavioral sensitization to amphetamine follows chronic administration of the CB1 agonist WIN 55,212-2 in Lewis rats, *Pharmacol. Biochem. Behav.* 73 (2002) 835–842.
- [22] M. Naassila, O. Pierrefiche, C. Ledent, M. Daoust, Decreased alcohol self-administration and increased alcohol sensitivity and withdrawal in CB1 receptor knockout mice, *Neuropharmacology* 46 (2004) 243–253.
- [23] I. Racz, A. Bilkei-Gorzo, Z.E. Toth, K. Michel, M. Palkovits, A. Zimmer, A critical role for the cannabinoid CB1 receptors in alcohol dependence and stress-stimulated ethanol drinking, *J. Neurosci.* 23 (2003) 2453–2458.
- [24] F. Rodriguez de Fonseca, M.R. Carrera, M. Navarro, G.F. Koob, F. Weiss, Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal, *Science* 276 (1997) 2050–2054.
- [25] M. Sato, C.C. Chen, K. Akiyama, S. Otsuki, Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis, *Biol. Psychiatry* 18 (1983) 429–440.
- [26] M. Sato, Y. Numachi, T. Hamamura, Relapse of paranoid psychotic state in methamphetamine model of schizophrenia, *Schizophr. Bull.* 18 (1992) 115–122.
- [27] H.H. Schmid, P.C. Schmid, V. Natarajan, N-Acylated glycerophospholipids and their derivatives, *Prog. Lipid. Res.* 29 (1990) 1–43.
- [28] J.C. Sipe, K. Chiang, A.L. Gerber, E. Beutler, B.F. Cravatt, A missense mutation in human fatty acid amide hydrolase associated with problem drug use, *Proc. Natl. Acad. Sci. U.S.A.* 99 (2002) 8394–8399.
- [29] D.J. Spencer, Cannabis-induced psychosis, *Int. J. Addict.* 6 (1971) 323–326.
- [30] G. Tanda, P. Munzar, S.R. Goldberg, Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys, *Nat. Neurosci.* 3 (2000) 1073–1074.
- [31] E.A. Thomas, B.F. Cravatt, P.E. Danielson, N.B. Gilula, J.G. Sutcliffe, Fatty acid amide hydrolase, the degradative enzyme for anan-

- damide and olcamide, has selective distribution in neurons within the rat central nervous system, *J. Neurosci. Res.* 50 (1997) 1047–1052.
- [32] D.A. Treffert, Marijuana use in schizophrenia: a clear hazard, *Am. J. Psychiatry* 135 (1978) 1213–1215.
- [33] H. Ujike, Stimulant-induced psychosis and schizophrenia: the role of sensitisation, *Curr. Psychiatry Rep.* 4 (2002) 177–184.
- [34] H. Ujike, Y. Morita, Cannabinoid receptors and schizophrenia, *J. Pharmacol. Sci.*, in press.
- [35] H. Ujike, M. Takaki, K. Nakata, Y. Tanaka, T. Takeda, M. Kodama, Y. Fujiwara, A. Sakai, S. Kuroda, CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia, *Mol. Psychiatry* 7 (2002) 515–518.
- [36] H. Ujike, M. Sato, Clinical features of sensitization phenomenon observed in patients with methamphetamine dependence and psychosis, *Ann. N. Y. Acad. Sci.* 125 (2004) 279–287.
- [37] J. Vinklerova, J. Novakova, A. Sulcova, Inhibition of methamphetamine self-administration in rats by cannabinoid receptor antagonist AM 251, *J. Psychopharmacol.* 16 (2002) 139–143.
- [38] T. Yamaguchi, Y. Hagiwara, H. Tanaka, T. Sugiura, K. Waku, Y. Shoyama, S. Watanabe, T. Yamamoto, Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice, *Brain Res.* 909 (2001) 121–126.
- [39] S. Zammit, P. Allebeck, S. Andreasson, I. Lundberg, G. Lewis, Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study, *BMJ* 325 (2002) 1199.
- [40] K. Zavitsanou, T. Garrick, X.F. Huang, Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia, *Prog. Neuropsychopharmacol. Biol. Psychiatry* 28 (2004) 355–360.

Association Between the Glutathione S-Transferase M1 Gene Deletion and Female Methamphetamine Abusers

Hiroki Koizumi,¹ Kenji Hashimoto,^{1*} Chikara Kumakiri,¹ Eiji Shimizu,¹ Yoshimoto Sekine,^{2,10} Norio Ozaki,^{3,10} Toshiya Inada,^{4,10} Mutsuo Harano,^{5,10} Tokutaro Komiyama,^{6,10} Mitsuhiro Yamada,^{7,10} Ichiro Sora,^{8,10} Hiroshi Ujike,^{9,10} Nori Takei,² and Masaomi Iyo^{1,10}

¹Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan

²Department of Psychiatry and Neurology, Hamamatsu University School of Medicine, Hamamatsu, Japan

³Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan

⁴Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan

⁵Department of Neuropsychiatry, Kurume University School of Medicine, Kurume, Japan

⁶National Center Hospital for Mental, Nervous, and Muscular Disorders, National Center of Neurology and Psychiatry, Kodaira, Japan

⁷Karasuyama Hospital, Showa University School of Medicine, Tokyo, Japan

⁸Division of Psychobiology, Tohoku University Graduate School of Medicine, Sendai, Japan

⁹Department of Neuropsychiatry, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan

¹⁰Japanese Genetics Initiative for Drug Abuse (JGIDA), Okayama, Japan

Several lines of evidence suggest that increased generation of auto-oxidized dopamine (DA) *o*-quinone is associated with the neurotoxicity of methamphetamine (MAP) in the brain, and that, as a cellular defenses against DA-derived quinines, glutathione S-transferase (GST) detoxifies auto-oxidized DA *o*-quinone in the brain. Glutathione S-transferase M1 (GSTM1) of the mu-class of GSTs catalyzes reaction between glutathione and catecholamine *o*-quinones under physiological conditions. This study was undertaken to investigate the role of the *GSTM1* gene deletion polymorphism in the neuropathology of MAP abuse. One hundred fifty-seven MAP abusers and 200 healthy comparison subjects were tested for a genetic polymorphism of *GSTM1*. The difference in the frequency of deletion (D)/non-deletion (N) alleles between the female abusers and female controls was close to statistical significance ($P = 0.071$), although there was no statistical difference ($P = 0.651$)

between male abusers and male controls. Furthermore, the number of female abusers with deletion alleles was significantly ($P = 0.007$, odds ratio: 2.77, 95% CI 1.30–5.89) higher than that of male abusers with deletion alleles. These findings suggest that *GSTM1* gene deletion may contribute to a vulnerability to MAP abuse in female subjects, but not in male subjects.

© 2003 Wiley-Liss, Inc.

KEY WORDS: methamphetamine; drug abuse; glutathione S-transferase; gender difference

INTRODUCTION

Abuse of methamphetamine (MAP) is a growing problem worldwide. Some lines of evidence have suggested strong genetic contributions to drug abuse vulnerability [Uhl et al., 2002]. The application of brain imaging techniques to the study of drug abuse have demonstrated that the density of dopamine (DA) transporters is significantly reduced in the caudate/putamen of MAP abusers [Sekine et al., 2001; Volkow et al., 2001], suggesting that long-term use of MAP causes damage to dopaminergic neurons in the human brain. Furthermore, it has been shown that MAP-induced neurotoxicity in the brain has been shown to require striatum DA and to involve mechanisms associated with oxidative stress [Cadet and Brannock, 1998]. It is also known that DA is auto-oxidized and the corresponding DA *o*-quinone (aminochrome) is subse-

*Correspondence to: Dr. Kenji Hashimoto, Department of Psychiatry (K2), Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chiba 260-8670, Japan.
E-mail: hashimoto@faculty.chiba-u.jp

Received 24 April 2003; Accepted 29 August 2003

DOI 10.1002/ajmg.b.20148

quently generated; moreover, aminochrome and its subsequent product, DA *o*-semiquinone, elicit redox cycling which leads to the generation of reactive oxygen species, which in turn degenerate dopaminergic neurons [Graham et al., 1978; Smythies and Galzigna, 1998]. DA oxidation also results in the formation of DA *o*-quinone, which readily participates in nucleophilic addition reactions with sulfhydryl groups on free cysteine, glutathione, or cysteine found in protein including DA transporter [Graham et al., 1978; Hastings and Zigmond, 1994; Smythies and Galzigna, 1998; Whitehead et al., 2001]. In addition, it has been reported recently that DA auto-oxidation contributes to MAP-induced neurotoxicity to DA terminals, adding support to the role of DA and oxidative stress in this model [LaVoie and Hastings, 1999]. Taken together, it is likely that increased generation of DA *o*-quinone by DA auto-oxidation is associated with the neurotoxicity of MAP in the brain.

Glutathione S-transferase M1 (GSTM1) is a subtype of GSTs that detoxify xenobiotics by conjugating glutathione. It has been reported that GSTM1 catalyzes a glutathione conjugate of catecholamine *o*-quinones such as aminochrome [Smythies and Galzigna, 1998]. GSTM1 has an entire gene deletion polymorphism and its enzymatic activity is classified into three grades, i.e., a highly active genotype (homozygous non-deletion alleles; NN), a moderately active genotype (heterozygous non-deletion alleles; DN), and a null genotype (homozygous deletion alleles; DD) [McLellan et al., 1997]. Recently, it has been reported that the frequency of D allele of *GSTM1* gene in the patients with schizophrenia was significantly ($P=0.0075$) higher than that of normal controls, suggesting that *GSTM1* gene may be associated with an increased susceptibility to schizophrenia [Harada et al., 2001a]. Thus, it seems that differences in the *GSTM1* genotype may contribute to the development of MAP abuse. In order to verify a potential role of the *GSTM1* gene in the neuropathology by MAP abuse, we analyzed a polymorphism of the *GSTM1* gene in subjects with diagnosed MAP-related disorders and in control groups.

MATERIALS AND METHODS

The research was performed after obtaining approval from the ethics committees of each institute of Japanese Genetics Initiative for Drug Abuse (JGIDA), and all subjects provided written informed consent for the use of their DNA samples for this research. The subjects were 157 patients (125 males, age: 37 ± 11 years (mean \pm SD), age range: 19–69 years; and 32 females, age: 28 ± 5 years (mean \pm SD), age range: 21–47 years) with MAP dependence and psychotic disorder meeting ICD-10-DCR criteria (F15.2 and F15.5) who were outpatients or inpatients of psychiatric hospitals of JGIDA, and 200 age-, gender- and geographical origin-matched normal controls (157 males, age: 37 ± 11 years (mean \pm SD), age range: 19–69 years; and 43 females, age: 36 ± 10 years (mean \pm SD), age range: 21–58 years) mostly consisted of medical staffs who had no past history and no family history of drug dependence or psychotic disorders. All

subjects were Japanese, born and living in restricted areas of Japan including northern Kyusyu, Setouchi, Tyukyuu, Toukai, and Kantou.

The polymorphism studied in this project was the deletion of the entire *GSTM1* gene. Genotyping for this gene was performed by a combination of two types of polymerase chain reaction (PCR) amplification as reported previously [Harada et al., 2001a,b]. The first type of PCR was used for the detection of a non-deletion allele with the appropriate primers (forward: 5'-CTTCACGTGTTATGGAG GTTC-3', reverse: 5'-GCGAGTTATTCTGTGTGTAGC-3'). The other type of PCR was used for the detection of a deletion allele with suitable primers (forward: 5'-ACAGAGGAAGGGTG-CATTTGATA-3', reverse: 5'-GACATTCATTCCCAA-GCGACCA-3'); both types of PCR were followed by agarose gel electrophoresis with ethidium bromide staining. Allele frequencies were calculated by gene counting and the differences between groups were evaluated by Fisher's exact test. The odds ratio (OD) and 95% confidence intervals were calculated to evaluate the effects of the different genotypes.

RESULTS

The *GSTM1* genotypes and the allele frequencies in MAP abusers and controls are shown in Table I. The genotype distribution in both abusers and controls was within the Hardy-Weinberg equilibrium. We found that a difference in the frequency of deletion (D)/non-deletion (N) alleles between the female abusers and female controls was a trend toward a statistical significance ($P=0.071$). In contrast, there was no significant difference between male abusers and male controls ($P=0.651$). The frequency of carrying the D allele among female abusers was significantly higher than that in male abusers ($P=0.007$, odds ratio: 2.77, 95% CI 1.30–5.89), whereas no gender difference was shown among control subjects ($P=0.297$, odds ratio: 1.36, 95% CI 0.80–2.31). The genotype distribution difference between female abusers and female controls was significant ($P=0.032$), whereas no significant difference between male abusers and male controls was shown ($P=0.819$).

DISCUSSION

Our findings suggest that a deletion of the *GSTM1* gene may contribute to MAP abuse vulnerability in female, but not in male, subjects. Based on the role played by *GSTM1* in the antioxidant system preventing neurotoxicity, *GSTM1* gene deletion might lead to an excess of catecholamine *o*-quinones (e.g., aminochrome) that are neurotoxic in the brain, including DA neurons. The reason underlying this gender difference is currently unclear. However, recent evidence has been suggestive of gender differences in course of drug dependence and drug abuse [Lynch et al., 2002]. It has been reported that females enter treatment programs after fewer years of amphetamine use, and that females also take less time to become addicted after initial use than do males [Westermeyer and Boedicker,

TABLE 1. Allele and Genotype Frequencies of the *GSTM1* Gene Deletion Polymorphism in MAP Abusers and Controls

	Male		Female	
	Abusers (n = 125)	Controls (n = 157)	Abusers (n = 32)	Controls (n = 43)
GSTM1 allele frequency				
D	172 (68.8%)	210 (66.9%)	55 (85.9%)	63 (73.3%)
N	78 (31.2%)	104 (33.1%)	9 (14.1%)	23 (26.7%)
	<i>P</i> = 0.651		<i>P</i> = 0.071	
GSTM1 genotype frequency				
DD	58 (46.4%)	67 (42.7%)	24 (75.0%)	21 (48.8%)
DN	56 (44.8%)	76 (48.4%)	7 (21.9%)	21 (48.8%)
NN	11 (8.8%)	14 (8.9%)	1 (3.1%)	1 (2.3%)
	<i>P</i> = 0.819		<i>P</i> = 0.032*	

GSTM1, glutathione S-transferase M1; MAP, methamphetamine; D, deletion allele; N, non-deletion allele.
**P* < 0.05.

2000]. In addition, positive subjective effects of D-amphetamine are enhanced during the follicular phase, which correlates with changes in estrogen levels [Lynch et al., 2002].

It has been suggested that gonadal hormones such as estrogen play a role in the differences between males and females regarding responses to drugs of abuse [Lynch et al., 2002]. In females, there is an accelerated transition from controlled to uncontrolled use, namely, dependence, and that gonadal hormones, particularly estrogen, may play a role in these processes [Justice and De Wit, 2000]. In studies using rats, estrogen has been revealed to enhance the behavioral and neurochemical responses to MAP by increasing stimulated DA release [Becker, 1999]. Furthermore, recent studies using brain imaging technique revealed that women have higher levels of DA transporters [Mozley et al., 2001] and lower DA D₂ receptor affinity in the striatum than men [Pohjalainen et al., 1998], suggesting a lower baseline of dopaminergic tone and elevated levels of DA released by MAP in females. Therefore, it is likely that gonadal hormones and gender differences in dopaminergic systems may be implicated in gender differences related to susceptibility to addiction to psychomotor stimulants. Thus, it appears that excess DA released by MAP might generate an excess of DA *o*-quinone, rendering it especially difficult for persons with low-activity GST to detoxify a sufficient amount of DA *o*-quinone. Furthermore, the *GSTM1* deletion would influence the susceptibility of females to MAP abuse.

In conclusion, our findings suggest that *GSTM1* gene deletion may contribute to a vulnerability to MAP abuse in female subjects, but not in male subjects.

REFERENCES

Becker JB. 1999. Gender differences in dopaminergic function in striatum and nucleus accumbens. *Pharmacol Biochem Behav* 64:803-812.
 Cadet JL, Brannock C. 1998. Free radicals and the pathobiology of brain dopamine systems. *Neurochem Int* 32:117-131.
 Graham DG, Tiffany SM, Bell WR Jr, Gutknecht WF. 1978. Auto-oxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. *Mol Pharmacol* 14:644-653.

Harada S, Fujii C, Hayashi A, Ohkoshi N. 2001a. An association between idiopathic Parkinson's disease and polymorphisms of phase II detoxification enzymes: Glutathione S-transferase M1 and quinone oxidoreductase 1 and 2. *Biochem Biophys Res Commun* 288:887-892.
 Harada S, Tachikawa H, Kawanishi Y. 2001b. Glutathione S-transferase M1 gene deletion may be associated with susceptibility to certain forms of schizophrenia. *Biochem Biophys Res Commun* 281:267-271.
 Hastings TG, Zigmund MJ. 1994. Identification of catechol-protein conjugates in neostriatal slices incubated with [³H]dopamine: Impact of ascorbic acid and glutathione. *J Neurochem* 63:1126-1132.
 Justice AJ, De Wit H. 2000. Acute effects of D-amphetamine during the early and late follicular phases of the menstrual cycle in women. *Pharmacol Biochem Behav* 66:509-515.
 LaVoie MJ, Hastings TG. 1999. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: Evidence against a role for extracellular dopamine. *J Neurosci* 19:1484-1491.
 Lynch WJ, Roth ME, Carroll ME. 2002. Biological basis of sex differences in drug abuse: Preclinical and clinical studies. *Psychopharmacol* 164:121-137.
 McLellan RA, Oscarson M, Alexandrie AK, Seidegård J, Evans DAP, Rannug A, Ingelman-Sundberg M. 1997. Characterization of a human glutathione S-transferase μ cluster containing a duplicated *GSTM1* gene that causes ultrarapid enzyme activity. *Mol Pharmacol* 52:958-965.
 Mozley LH, Gur RC, Mozley PD, Gur RE. 2001. Striatal dopamine transporters and cognitive functioning in healthy men and women. *Am J Psychiatry* 158:1492-1499.
 Pohjalainen T, Rinne JO, Nagren K, Lehtikainen P, Anttila K, Syvalahti EK, Hietala J. 1998. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. *Mol Psychiatry* 3:256-260.
 Sekine Y, Iyo M, Ouchi Y, Matunaga T, Tsukada H, Okada H, Yoshikawa E, Futatsubashi M, Takei N, Mori N. 2001. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. *Am J Psychiatry* 158:1206-1214.
 Smythies J, Galzigna L. 1998. The oxidative metabolism of catecholamines in the brain: A review. *Biochim Biophys Acta* 1380:159-162.
 Uhl GR, Liu QR, Naiman D. 2002. Substance abuse vulnerability loci: Converging genome scanning data. *Trends Genet* 18:420-425.
 Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, Sedler MJ, Gateley SJ, Hitzemann R, Ding YS. 2001. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. *Am J Psychiatry* 158:377-382.
 Westermeyer J, Boedicker AE. 2000. Course, severity, and treatment of substance abuse among women versus men. *Am J Drug Alcohol Abuse* 26:523-535.
 Whitehead RE, Ferrer JV, Javitch JA, Justice JB. 2001. Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter. *J Neurochem* 76:1242-1251.

Clinical Features of Sensitization to Methamphetamine Observed in Patients with Methamphetamine Dependence and Psychosis

HIROSHI UJIKE^a AND MITSUMOTO SATO^b

^a*Department of Neuropsychiatry, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan*

^b*Department of Psychiatry, Tohoku Fukushi University, Sendai, Japan*

ABSTRACT: Methamphetamine (METH) has been the most popular drug of abuse in Japan for more than 50 years, resulting in serious health and social issues. Most adult abusers in Japan consume only METH; multiple-substance abusers are rare. This unusual aspect of drug abuse makes it possible to observe clearly the sequential alteration of psychiatric symptoms induced by METH without modification by other illegal drugs. Clinical investigation reveals three core characteristics of METH abuse: (1) progressive qualitative alteration in mental symptoms from a nonpsychotic to a prepsychotic to a severely psychotic state; (2) enhanced vulnerability to relapse of psychosis; and (3) very long duration of the vulnerability to relapse. These findings indicate that the phenomenon of sensitization to METH develops during abuse and plays a key role in the susceptibility to and onset of psychosis and in the refractory process. Molecular findings using animal sensitization models may facilitate a better understanding of, and open the way for innovative therapies for, METH psychosis and also chronic schizophrenia.

KEYWORDS: sensitization phenomenon; drug abuse; methamphetamine psychosis; vulnerability to relapse

INTRODUCTION

Abuse of amphetamines has been a serious health and social concern for more than 50 years in Japan. Among amphetamine derivatives, methamphetamine (METH) is the primary one consumed in Japan. Police records of the total number of people arrested each year for illegal METH consumption or possession reveal three epidemics of METH abuse (FIG. 1). The first epidemic broke out just after World War II and continued until 1957. In this epidemic, a METH product synthesized by a domestic pharmaceutical company was distributed in ampoules on the open market; it was 100% pure and injected intravenously. This epidemic reached a peak in 1954. In that year, more than 55,000 persons were arrested, and the estimated

Address for correspondence: H. Ujike, M.D., Ph.D., Department of Neuropsychiatry, Okayama University Graduate School of Medicine and Dentistry, 2-5-1 Shikata-cho, Okayama 700-8558, Japan. Voice: +81-86-235-7242; fax.: +81-86-235-7246.
hujike@cc.okayama-u.ac.jp

Ann. N.Y. Acad. Sci. 1025: 279–287 (2004). © 2004 New York Academy of Sciences.
doi: 10.1196/annals.1316.035




FIGURE 1. Methamphetamine (METH) abuse in Japan. Based on Japanese police records of the number of persons arrested annually for illegal drug abuse.

number of METH abusers was over half a million. The Japanese government sounded a note of warning against METH abuse with the slogan "METH brings national ruin." After 1954, the police tightened drug controls, and METH abuse dramatically subsided. However, METH abuse began to rise again from about 1970, and the second epidemic peaked in 1984. The second epidemic was characterized by promotion by Yakuza, members of the Japanese Mafia. They smuggled illegally made Korean or Taiwanese METH in crystal form into Japan and supplied it to abusers. It was dissolved in water and injected intravenously. Heinous crimes by METH abusers increased and became a serious social problem. After 1984, METH abuse appeared to decrease slowly, but it started to increase again from 1995, becoming the third epidemic, which continues up to the present. The third epidemic is characterized by the entry of Iranian drug dealers using cellular phones into the market, in addition to the Yakuza. This new distribution method made drug control very difficult and resulted in an increase in hidden abusers. A further factor was that the Iranian dealers were friendlier to teenagers than the Japanese Yakuza. Therefore, it seemed safe and easy to get drugs from them, and high school students started to use METH casually to lose weight or just for fun.

On the other hand, multiple-substance abuse has been rare in Japan. METH has been the most popular illicit drug for at least the last 10 years (FIG. 2), followed by organic solvent inhalation. Although recent reports emphasize a rapid increase of cannabinoid, morphine, and cocaine abuse in Japan, the total number arrested for abuse of these drugs is still quite small—less than 10% of that of METH abusers.




FIGURE 2. Substances abused in Japan.

Organic solvents are inhaled mostly by young and middle teenagers, rarely by adults. These facts indicate that most adult Japanese drug abusers have been consuming METH exclusively. This characteristic of Japanese drug abuse makes it possible to observe the sequential alteration of psychiatric responses to METH and the clinical course of the "pure form" of METH psychosis. Many excellent clinical studies have been published,¹⁻⁴ unfortunately mostly in Japanese; and they consistently reveal that longer and more frequent consumption of METH induces psychosis at a higher rate, more prompt relapse due to subsequent consumption, more frequent spontaneous relapse, and a worse prognosis. These clinical findings indicate development of sensitization during METH abuse and that this sensitization plays a central role in the etiology of METH psychosis. We present here three typical cases of METH psychosis and extract core clinical features of the sensitization observed in individual cases suffering from METH psychosis.

CASE REPORTS

Case 1: Male, 28 Years Old

At the age of 21, he began to inject intravenous METH 2-3 times a day (40-150 mg/injection).⁵ After injecting, he felt relaxed and as if he were floating. He craved stimulation and felt generous. He drove cars at high speed for the thrill. In withdrawal, he crashed and became lethargic. Three years after beginning METH abuse (at the age of 24), he began to feel something was wrong. He felt that someone was hiding upstairs or that policemen were surrounding his house, but he found no one there. At the age of 25, he still abused METH periodically. His abnormal experiences increased at every injection. He became sure that policemen were surround-

ing his house and trying to arrest him. He became frantic and finally set a house on fire to escape.

In this case, the initial dose of METH induced stimulating effects that were enhanced by subsequent METH doses; but after three years of METH abuse, METH injections produced delusions that increased over time.

Case 2: Male, 46 Years Old

At the age of 13, he inhaled an organic solvent several times. At the age of 24, he began to inject METH intravenously.⁵ After injection, he felt his hair stand on end. His libido and sexual sensations were greatly enhanced. He became garrulous and felt able to concentrate much better. During METH abuse, he participated enthusiastically in gambling and sexual intercourse. At the age 25, he was arrested several times but continued the abuse. He did not suffer from hallucinations or delusions at that time. At the age of 26, he had an auditory hallucination of a lady's voice while he was taking a shower. He heard her say, "Don't take drugs. You are worthless. Kill yourself." Because of the auditory hallucinations, he tried to stop using METH but failed. At the age of 36, he began to hallucinate after every injection, and the hallucinations lasted more than 24 hours.

One day, he encountered a space alien and found 11 holes in his own body after injection. The space alien entered his body through the holes and talked to him. He punched the alien, but he later found that his aunt was dead. He mistook his aunt for an alien under hallucination. At the age of 43, he married and stopped using METH for three years. His psychotic symptoms completely disappeared. However, at the age of 46, he consumed METH again, and his auditory and visual hallucinations recurred after only a couple of METH injections. He went on a rampage because he mistook policemen for aliens.

This case also shows that repeated METH injection produced stimulating effects at first but, later, hallucinations and delusions. The latency between the initial consumption of the drug and the onset of psychosis was two years in the first episode; but in the relapse after abstinence, only a few injections were enough to induce psychosis. Accordingly, susceptibility to relapse had developed in his brain during abuse of the drug.

Case 3: Male, 29 Years Old

At the age of 22, he began to inject METH (about 40 mg/injection) intravenously.⁵ Just after injection, he felt very clear headed and repeated certain behaviors compulsively. While using METH, he was absorbed in gambling. When he consumed an overdose of METH, he felt anxious and noticed signs that people might be attacking him. At the age of 23, he injected several times a day because it highly enhanced his sexual sensation. He found that merely inhaling METH stimulated him. At the age of 24, he became aware of a voice saying, "Are you all right?" after injecting METH. At that time, he was uncertain whether the voice was illusory or real. However, at the age of 25, he began to suffer from auditory hallucinations after every METH injection. He heard a voice say, "Your wife had an affair. Kill her!"

At the age of 27, he was arrested and jailed. In prison, his hallucinations reappeared despite complete abstinence. At the age of 28, he was released from prison.

Although he has not abused METH since, his hallucinations have not disappeared. He has complained, "The TV is talking to me," "Somebody is trying to attack me," "My reflection in the window turns into the devil, and my wife sees it and runs away," and "My food has been poisoned by someone." He was arrested again, but a urine test in police custody did not detect METH.

This person suffered a relapse of psychosis while he was jailed. Japanese jails are strictly controlled, and prisoners are never able to get drugs. Therefore, he suffered from spontaneous relapse without resumption of METH use, demonstrating that longer and heavier abuse increases susceptibility to spontaneous relapse.

CORE CLINICAL FEATURES OF SENSITIZATION TO METH IN PATIENTS

Three core features of the sensitization phenomenon in METH psychosis are observed in these three cases: (1) induction of a progressive qualitative alteration in mental symptoms, (2) enhancement of vulnerability to relapse of the psychosis, and (3) very long duration of the vulnerability to relapse. These features reflect different clinical aspects of the sensitization induced by METH abuse and were observed in detail in our recent clinical investigation of patients with METH dependence and psychosis in the third epidemic.

Progressive Qualitative Alteration in Induced Mental Symptoms

The clinical course shown in these three cases is illustrated in FIGURE 3.⁶ Repeated consumption of METH induces psychotomimetic effects such as feelings of stimulation and increased concentration in the abuser initially, and these effects are gradually enhanced by subsequent doses of METH. However, after a certain point, further consumption of METH no longer induces psychotomimetic effects, but psychotic symptoms. Prepsychotic abnormal experiences without certainty, such as delusional moods or ideas of reference, are seen first and then shift to a completely psychotic state consisting of potent delusions—for example, delusions of reference, persecution, and poisoning; and auditory and visual hallucinations after further use of METH. Accordingly, METH-induced psychiatric symptoms show progressive quantitative alteration from a nonpsychotic to a prepsychotic and finally to a psychotic state. The rate of psychosis due to METH is reported to be as high as 76–92%.^{1–3,7,8} Unexpectedly, the rates in the first and second epidemic were almost the same despite the fact that a 100% pure pharmaceutical company product and an impure, illicitly manufactured, underground METH were consumed in the first and second epidemics, respectively. Connell⁹ reported similarly high rates of psychosis due to oral amphetamine consumption. The period of latency between the initial use and the onset of psychosis varies from as little as several weeks to as much as 20 years because it is greatly influenced by the dose of METH, frequency of consumption, route of administration (intravenous injection, oral, inhalation), circumstances of abuse, and individual vulnerability to psychosis. Our present study showed that the average latency was 5.2 ± 5.9 years ($N = 149$) and that the risk of psychosis seemed to rise steeply when the duration of METH use exceeded 6 months (TABLE 1). Actually, case 2 developed psychosis after 2 years abuse of METH.

TABLE 1. Clinical course of methamphetamine-induced psychosis in three epidemics

	Epidemic 1	Epidemic 2	Epidemic 3
Study	Tatetsu ²	Sato ⁸	Ujike
Year	1956	1982	2003
<i>Latency from METH abuse to initial psychotic episode</i>			
Number of patients	<i>N</i> = 100	<i>N</i> = 35	<i>N</i> = 149
<1 week	—	0	1
1–4 weeks	6	0	7
1–3 months	19	9	7
4–6 months	23	9	4
6–12 months	27	3	17
>1 year	25	79	64
<i>Time for recovery from psychosis after METH discontinued</i>			
Number of patients	<i>N</i> = 74	<i>N</i> = 82	<i>N</i> = 170
0–10 days	} 77	64	} 59
11–30 days		18	
>1 month ^a	23	18	41 ^b

^aProlonged type.

^b11% in 1–3 months, 2% in 3–6 months, and 28% >6 months.

Enhanced Vulnerability to the Relapse of Psychosis

METH-induced psychosis usually disappears shortly after the discontinuance of METH consumption and the beginning of neuroleptic treatment. However, even after complete recovery, relapse develops very promptly after subsequent doses of METH. We found that the relapse latency from reconsumption of METH was less than one week for 60% of patients and less than one month for 80% of patients (*N* = 101), intervals that are much shorter than the latency of the initial psychosis, which was more than one year for the majority of patients (TABLE 1). As shown by case 2, the initial psychosis occurred after two years of METH use, but relapse occurred only one week after resumption of METH consumption. These data demonstrate that severe vulnerability to relapse of METH psychosis must develop during METH abuse. As shown in case 3, longer METH abuse can induce a spontaneous relapse due to an unspecific stressor, such as jail detention, without METH consumption. It is reported that spontaneous relapse may also occur after severe insomnia or heavy alcohol consumption. Our data showed that patients with spontaneous relapse usually had a history of more than two years of METH abuse. Our data also showed that the longer the duration of METH abuse, the worse the prognosis of psychosis. Users usually recover from METH psychosis within one week, or one month at the longest, after cessation of METH consumption; this is called transient-type METH psychosis. However, recovery of patients with longer METH consumption from psychosis may sometimes be delayed to over one month, or occasionally over 6 months, which are called the prolonged and persistent types, respectively. The rate of the prolonged/




FIGURE 3. Longitudinal profiles of behavioral sensitization to methamphetamine (METH) in experimental animals, methamphetamine-induced psychosis, and patients with chronic schizophrenia.⁶

persistent type of METH psychosis was 23% in the first epidemic,² but it was decreased to 18% in the second epidemic⁸ by the introduction of neuroleptics. However, our study of the third epidemic showed that the rate of prolonged/persistent METH psychosis rose to 41%, more than twice that of the second epidemic. We found that considerable numbers of patients in the third epidemic had consumed METH periodically since the second epidemic, which resulted in an increase in the number of patients who abuse METH for more than 10 years. This is why the percentage of patients with a worse prognosis for METH psychosis has increased in the third epidemic. Thus, longer and heavier abuse of METH delays recovery and worsens the prognosis for METH psychosis.